Biogen Inc at JPMorgan Healthcare Conference Transcript
Good afternoon, everybody. I'm Chris Schott from JPMorgan, and it's my pleasure to be introducing Biogen today. We have the company's CEO, Chris Viehbacher, who's going to talk about the progress the company's made across its portfolio.
So Chris, Happy New Year. Looking forward to the presentation. We'll jump to a Q&A session once Chris is done.
Thank you, Chris. Happy New Year, everybody. I think I should be well managed here. I've got my current Head of IR and my prior Head of IR from Sanofi here with me to make sure I don't screw up.
All right, so exciting year at Biogen. We've been on a long journey. Obviously, the MS portfolio has been declining. I think the first year I was here as CEO of Biogen, we talked about the melting iceberg. And this is a period where every pharma company gets at one point where the growth drivers of your business are arriving at the end of their intellectual property lives
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
